S
uicide is a growing public health problem, with the national rate in the United States increasing by 30% from 2000 to 2016 (1) . According to data from the Centers for Disease Control and Prevention, the national suicide rate increased from 10.4 to 13.5 per 100 000 persons, with average annual increases of 1% from 2000 to 2006 and 2% from 2006 to 2016. Findings from a 2017 survey by the Substance Abuse and Mental Health Services Administration (SAMHSA) suggest that suicidal ideation, suicide planning, and suicide attempts have especially increased over the past 10 years among persons aged 18 to 25 years (2) . The SAMHSA notes that these increases have co-occurred with an increase in the prevalence of mental health conditions that cause significant impairment in daily functioning, especially major depressive episodes and chronic substance abuse.
This systematic review (SR) served to update the 2013 clinical practice guideline (CPG) from the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) on assessment and management of suicide risk. Because this SR supports an update, the literature searches were intended to cover the period from the previous CPG searches to immediately before the guideline panel meeting. The key questions (KQs) addressed in this review were developed by the VA/DoD workgroup for the suicide management CPG. The specific questions are listed in the Appendix (available at Annals.org). The full CPG covers a range of recommendations pertaining to screening, assessment of risk factors, and interventions and treatments intended to mitigate risk for suicide. This article focuses specifically on the evidence from that review that assessed the benefits and harms of nonpharmacologic and pharmacologic treatments for persons at risk for suicide.
METHODS
This SR focused on various nonpharmacologic and pharmacologic interventions compared with no intervention, wait-list control, placebo, other active medication or nonpharmacologic intervention, or combination medication plus nonpharmacologic treatment. Consistent with the methods outlined in the VA/DoD Guideline for Guidelines (3) , the first line of evidence was previously published SRs. For interventions of interest, we selected the most recent, relevant, and comprehensive SR that was rated by a validated assessment tool as having good methodological quality (4) . If there were multiple good-quality SRs for a given intervention with similar arrays of included studies, we chose the most comprehensive (in terms of the number of high-quality studies included) and/or recent SR for our evidence synthesis to avoid multiple ratings of a similar evidence base. Systematic reviews were supplemented with subsequently published randomized controlled trials (RCTs). Any RCTs that were included in the SRs were not considered independently as evidence in this review. For interventions for which no SR was available, we summarized the overall findings of RCTs that addressed the intervention and reported on at least 1 outcome of interest.
Data Sources and Searches
The current review serves to update the evidence supporting the VA/DoD's previous CPG on assessment and management of suicide risk. The end date of the literature search in the previous guideline was 18 November 2011; our searches encompassed this period and extended through May 2018. We searched MEDLINE and EMBASE (via Embase.com), MEDLINE InProcess and PubMed-unique content (via PubMed .gov), PsycINFO, the PILOTS (Published International Literature on Traumatic Stress) database, the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials, and the Health Technology Assessment Database. A search of ClinicalTrials.gov through February 2019 did not identify any additional relevant studies. Clinical experts serving as members of the guideline workgroup were also asked to identify any important publications published after our search date during the guideline development process. Search terms are provided in Appendix Tables 1 to 3 (available at Annals.org).
Study Selection
Literature was screened using DistillerSR (Evidence Partners). The titles and abstracts identified in the literature search were screened for relevancy against the inclusion and exclusion criteria, and relevant titles underwent full-text review. All disagreements were resolved by consensus between 2 screeners.
We used a PICOTS (population, intervention, comparator, outcomes, timing of outcomes measurement, and setting) approach to identify studies that met our inclusion criteria. The population of interest was adults (aged ≥18 years) at risk for suicide. Interventions included nonpharmacologic and pharmacologic therapies. Nonpharmacologic interventions of interest were psychotherapies, crisis response planning (CRP), and community support programs. Pharmacologic interventions of interest were antidepressants and anxiety medications, lithium, antipsychotics, ketamine, and naloxone. Comparators of interest were no treatment (for example, placebo or wait list), other active therapies or combination medication, and nonpharmacologic treatments. Critical outcomes included suicides, suicide attempts, suicidal ideation, harms (such as reduction of health-seeking behavior and effect on patient-provider relationship, career, social relationships, and functioning), overdose, and hopelessness.
Studies were limited to English-language SRs or RCTs with no minimum follow-up that took place in an outpatient health care setting, including primary care, emergency care, VA, community, and specialty care settings.
Data Extraction and Risk-of-Bias Assessment
One investigator extracted study data, and a senior reviewer verified the accuracy of the extractions. For individual RCTs not included in the SRs, we abstracted the following study-level details: country, purpose, and risk-of-bias (ROB) rating. For SRs, we reported on the search strategy; study selection criteria; and overall information about the evidence base, including the number of included studies, the overall number of patients enrolled, and the ROB assessment. For RCTs and SRs, we also abstracted data on the population, interventions, and results.
One investigator assessed the ROB of each SR using criteria developed by the U.S. Preventive Services Task Force (USPSTF) for SRs (4) . The ROB of individual RCTs not included in the SRs was rated as good, fair, or poor using criteria developed by the USPSTF for randomized trials (4) . For studies included in SRs, we relied on the quality assessments performed in the reviews and used the overall rating that was reported (good, fair, or poor). A senior reviewer verified the accuracy of the ROB ratings. Disagreements were resolved through discussion. Appendix Table 4 (available at Annals.org) shows ROB assessments.
Data Synthesis and Analysis
We used a narrative approach to synthesize the evidence for each intervention. We reported on metaanalysis results from SRs and examined the degree of heterogeneity identified through the analysis. Rather than conducting an updated meta-analysis, we examined whether the results of new studies were consistent (same direction and similar magnitude) with the findings of the prior SRs. The overall quality of the body of evidence supporting the findings for the outcomes of interest was assessed by the authors using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (5) . A senior reviewer verified the accuracy of the GRADE ratings. Disagreements were resolved through discussion.
Role of the Funding Source
This review was funded by the VA to support an update of the CPG on assessment and management of patients at risk for suicide to be used in VA and DoD clinical practice. These agencies helped refine the scope, informed KQ development, and reviewed a draft report of the findings. The authors are solely responsible for the content preparation, writing the manuscript, and the decision to submit the manuscript for publication.
RESULTS
Literature searches identified 5410 citations potentially addressing all of the KQs of interest for the guideline evidence review (see the Figure for the study flow). Overall, 70 studies addressed 1 or more of the KQs and were considered as evidence in the guideline review encompassing treatment, risk factors, and screening. Twenty-three articles were relevant to this SR.
Nonpharmacologic Interventions
Five SRs and 12 RCTs examined nonpharmacologic interventions for suicide prevention. These covered a range of interventions delivered one-to-one, within a small group or in a community setting (Tables 1 and 2 ). Included interventions were provided face-to-face, via the Internet, or through mobile telephone applications. Using the USPSTF criteria for SRs, we rated the quality of the 5 SRs as good. The overall quality of the included studies was rated as fair in 4 SRs (6 -9) and poor in 1 SR (10) . Study limitations included concerns about blinding, allocation concealment, participant attrition, and potential for reporting bias. Table 1 shows quality ratings for the body of evidence for each intervention. The quality of the included individual trials ranged from good to poor according to the USPSTF criteria. Two trials were rated as good (11, 12) , 6 were rated as fair (13) (14) (15) (16) (17) (18) , and 4 were rated as poor (19 -22) . Study limitations were related primarily to moderate to high participant attrition, lack of clarity about allocation concealment and blinding, and potential reporting bias. Supplement Tables 1 to 3 (available at Annals.org) provide full GRADE ratings and study information.
Cognitive Behavioral Therapy
Four SRs and 1 additional RCT examined treatment with cognitive behavioral therapy (CBT) for suicide behavior and prevention. One SR (10 RCTs; n = 1241) focused on the effects of CBT compared with treatment as usual (TAU) on suicide attempts in adults who had attempted suicide within 6 months of the study (6) . Another SR (22 RCTs; n = 1977) evaluated the effect of CBT delivered face-to-face or via the Internet compared with TAU or, in some studies, a nondirective control (for example, wait list or befriending) on suicidal ideation (7) . A third SR (6 RCTs; n = 1040) focused on the effect of CBT versus TAU on suicide prevention (8) . The final SR (18 RCTs; n = 3458) assessed the effect of CBT compared with TAU on hopelessness, suicidal ideation, and suicide (10) .
The RCT assessed the effectiveness of CBT compared with an attention-control program for prevention of suicidal ideation among medical interns with a mean age of 25 years (19) . Participants in the CBT group (n = 100) received 4 weekly Web-based sessions lasting 30 minutes each, and those in the attention-control group (n = 99) received 4 weekly e-mails containing information about depression and suicide and contact information for local mental health services.
The findings suggest that CBT reduced suicide attempts (risk ratio [RR], 0.47 [95% CI, 0.30 to 0.73]; P = 0.0009) (6), suicidal ideation (standardized mean difference [SMD], Ϫ0.24 [CI, Ϫ0.41 to Ϫ0.07] in 15 studies [7] and Ϫ0.32 [CI, Ϫ0.53 to Ϫ0.11] in 8 studies [10] ), and hopelessness (SMD, Ϫ0.31 [CI, Ϫ0.51 to Ϫ0.10]) (10) compared with TAU. The strength of the evidence for these outcomes was moderate ( Table 1) . However, CBT did not seem to prevent or reduce suicide (8, 10) ; the strength of evidence for this outcome was low. No harms related to CBT were reported in the included evidence. Further data (7) suggest a modest benefit of Internet-delivered CBT compared with nondirective controls (very low strength of evidence), but not when compared with TAU or CBT delivered face-to-face.
Dialectical Behavior Therapy
Dialectical behavior therapy (DBT) combines elements of CBT, skills training, and mindfulness techniques with the aim of helping persons with borderline personality disorder (BPD) develop skills in emotion regulation, interpersonal effectiveness, and distress tolerance. One SR (10) and 3 RCTs (13, 14, 20 ) assessed the efficacy of DBT for suicide behavior and prevention.
The SR included 5 RCTs (n = 222) that examined the efficacy of DBT among patients with BPD who were at high risk for suicide (10) . The included RCTs compared DBT with TAU (3 trials), client-oriented therapy (1 trial), less directive psychotherapy (1 trial), and DBT plus prolonged exposure therapy (1 trial). Two of the additional RCTs also assessed the efficacy of DBT in reducing suicidal behavior among patients diagnosed with BPD. One compared DBT skills training plus TAU (n = 42) versus TAU alone (n = 42) (13) , and the other compared DBT plus the Collaborative Assessment and Management of Suicidality framework (CAMS) (n = 57) versus CAMS alone (n = 51) (14) . The final RCT assessed the efficacy of DBT among veterans at high risk for suicide without a diagnosis of BPD (20). Veterans were randomly assigned to standard DBT for 6 months (n = 46) or treatment according to the recommendations of their mental health team (n = 45).
The findings for DBT suggest that it is more effective than client-oriented therapy (MD, Ϫ7.75 [CI, Ϫ14.66 to Ϫ0.84] in 1 RCT [n = 24] in the SR [10] ) and wait-list control (1 RCT [n = 84]; P < 0.04) (13) in reducing suicidal ideation. However, the overall quality of the evidence supporting this outcome was low. No differences were found between DBT and TAU, "expert-led" psychotherapy, or CAMS for suicidal ideation. Similarly, no differences were found between DBT and TAU or other psychotherapeutic interventions for hopelessness, suicide attempts, or death.
Brief Intervention
One SR included 3 RCTs (n = 2028) that compared the World Health Organization's Brief Intervention and Contact method (WHO-BIC) with an active control condition for suicide prevention (8) . The intervention included an educational session on suicide prevention followed by regular contact with a trained provider by telephone or in person for up to 18 months. The findings suggest that WHO-BIC reduced the incidence of suicide compared with the control condition (3 of 1041 vs. 24 of 987; odds ratio [OR], 0.20 [CI, 0.09 to 0.42]; P < 0.001).
Crisis Response Planning
An RCT evaluated the effectiveness of enhanced CRP (E-CRP) (n = 33) versus standard CRP (n = 32) or TAU (n = 32) for prevention of suicide attempts in patients with active suicidal ideation or a history of suicide attempt (18) . The TAU group used a verbal contract for safety along with risk assessment, supportive listening, and provision of crisis resources. The standard CRP group used the same components as the TAU group, but without the verbal contract for safety. The E-CRP group used the same components as the standard CRP group but also included an explicit discussion of the patient's reasons for living. The findings suggest a difference in the number and proportion of suicide attempts that favored CRP of either type versus TAU (hazard ratio, 0.24 [CI, 0.06 to 0.96]; P = 0.028) but no difference between E-CRP and standard CRP.
Window to Hope
One RCT evaluated the efficacy of a group psychological intervention called Window to Hope in reducing hopelessness and suicidal ideation among veterans with moderate to severe traumatic brain injury (11) . Participants were randomly assigned to receipt of ten 2-hour weekly sessions of Window to Hope (n = 15) or to a wait-list control (n = 20). The wait-list group continued to receive usual care from the VA until the start of group therapy. The average age of the veterans in this study was 51 years, and follow-up was 3 months. 
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Other Interventions
The evidence base for the interventions presented in Table 2 was small and was not used to inform any recommendations because of concerns about the low certainty of the evidence. Overall, the findings suggest no difference between the interventions and the control conditions.
Pharmacologic Interventions
Three SRs (23-25) and 3 RCTs (26 -28) evaluated the effectiveness of a range of pharmacotherapies for adult patients at risk for suicide ( Table 3) . Using the USPSTF criteria, we rated the quality of the SRs as good. The quality of the included studies was rated as fair overall in the 3 SRs. Study limitations were primarily related to lack of clarity surrounding randomization, allocation concealment, and blinding in the original trials, as well as study attrition and possible selective reporting of outcomes. Table 3 shows quality ratings for the body of evidence for each medication. Quality ratings ranged from fair to poor across the individual RCTs. Limitations of the studies rated as fair included lack of blinding of some patients (28) and lack of clarity about allocation concealment and blinding of outcome assessors (27). Limitations of the RCT rated as poor (26) included high attrition rates and unexplained diagnostic, pharmacologic, and therapeutic heterogeneity of the study population. Supplement Tables 4 to 6 (available at Annals.org) provide full GRADE ratings and study information. 
Other Medications
Two additional studies of pharmacologic treatments were identified but were not used to inform any recommendations because of concerns about very low certainty of the evidence, adverse effect profile, and lack of applicability to a U.S.-based patient population. One RCT examined the safety and efficacy of very low dosages of sublingual buprenorphine as a time-limited treatment for suicidal ideation, suicide attempt, and adverse events (26). The buprenorphine group had a greater reduction in Beck Scale for Suicide Ideation score than the placebo group after 4 weeks (MD, Ϫ7.1 [CI, Ϫ12.0 to Ϫ2.3]; P = 0.004). There was 1 suicide attempt in each group (difference not significant). Rates of treatment-related adverse events were higher in the buprenorphine group, and the most common adverse events were fatigue, nausea, dry mouth, and constipation. Finally, an SR compared a range of pharmacologic and natural products for patients with a history of selfharm (25) . The authors noted that data were not reported numerically in many of the included studies, which limited their ability to analyze outcomes. We report on the most complete available data on newergeneration antidepressants (NGAs), which include mianserin, nomifensine, and paroxetine. The findings suggest that there were no significant differences between NGAs and placebo (OR, 0.32 [CI, 0.01 to 8.04]) 
DISCUSSION
In this SR, we reviewed and synthesized evidence from 8 SRs and 15 RCTs of nonpharmacologic and pharmacologic interventions intended to prevent suicide in at-risk persons. These interventions are a subset of topics included in the updated VA/DoD 2019 CPG for assessment and management of patients at risk for suicide. The full final guideline is available from the VA Web site (www.healthquality.va.gov).
Nonpharmacologic interventions encompassed a range of approaches delivered either face-to-face or via the Internet or other technology. We found moderatestrength evidence supporting the use of face-to-face or Internet-delivered CBT in reducing suicide attempts, suicidal ideation, and hopelessness compared with TAU. We found low-strength evidence suggesting that CBT was not effective in reducing suicides. However, rates of suicide were generally low in the included studies, which limits our ability to draw firm conclusions about this outcome. Data from small studies provide low-strength evidence supporting the use of DBT over client-oriented therapy or control for reducing suicidal ideation. For other outcomes and other comparisons, we found no benefit of DBT. There was low-strength evidence supporting use of WHO-BIC to reduce suicide, CRP to reduce suicide attempts, and Window to Hope to reduce suicidal ideation and hopelessness.
We found moderate-strength evidence supporting use of short-term intravenous ketamine for reducing suicidal ideation and use of lithium for reducing suicide. Patients in a meta-analysis that used individual patient-level data (23) had diagnoses of major depressive disorder, bipolar disorder, or posttraumatic stress disorder with baseline suicidal ideation. Patients in 1 RCT had a diagnosis of major depressive disorder (28), and those in another RCT had recently been diagnosed with cancer (27). All trials in the meta-analysis and the RCTs excluded patients with a history of substance use disorder or past or current psychotic disorders, which limits generalizability to these high-risk populations. In a large SR, risk for suicide was significantly lower with lithium than placebo in patients with unipolar or bipolar mood disorders. However, compared with other active treatments for mood disorders, no benefits of lithium use were found. The data for these comparisons were highly variable and do not suggest that the treatments are equivalent.
Our review has several limitations. The methods underlying the SRs for VA/DoD guidelines rely on previously published SRs. Although a benefit of this is the ability to perform rapid reviews for formulating evidence-based recommendations, we were limited by what was reported in the SRs. When SRs addressing a question or outcome of interest were not available, we incorporated and synthesized data from published clinical trials. However, the time frame for conducting the SR did not allow us to perform quantitative synthesis; therefore, we provide a qualitative, narrative synthesis of the literature. In addition, our time frame did not allow for dual screening or dual ROB assessment. We addressed the former issue by using the DistillerAI function (Evidence Partners) to confirm that no studies were missed in the database and relied on iterative feedback from the guideline panel. To address the latter concern, a senior reviewer checked all ratings and made corrections as needed. Finally, the methods outlined in the VA/DoD Guideline for Guidelines (3) direct the approach of using existing SRs as the primary source of evidence in reviews supporting the VA/DoD CPGs. Using previously published SRs could result in potential bias, either by overrepresenting studies if they are reported in more than 1 review included in the final evidence synthesis or by missing important studies (29). We recognized this and attempted to reduce bias by including the most comprehensive, recent SRs with high methodological rigor; by also including studies that were published subsequent to the review; and by carefully assessing areas of overlap. We occasionally included reviews that overlapped provided that they reported on different outcomes or subgroups of interest. Typically, overlap in reviews is highlighted for the CPG workgroup panel to assist them in interpreting the overall findings.
Given the need for interventions to mitigate risk for suicide, particularly in the veteran and active military populations, the lack of evidence to support current nonpharmacologic and pharmacologic interventions and the lack of information on potential harms is significant. We found modest benefit of CBT and DBT in reducing suicidal ideation compared with TAU or wait-list control, and CBT also reduced suicide attempts compared with TAU. Both ketamine and lithium had modest benefit in reducing the rate of suicide compared with placebo. The data on ketamine are short-term, with follow-up of only 1 to 7 days in the SR and up to 6 weeks in 1 small RCT, and long-term information on patients treated with ketamine is not available. Recently, the U.S. Food and Drug Administration cleared the s-enantiomer of ketamine, esketamine, as a nasal spray for use in patients with treatment-resistant depression, and long-term follow-up studies may better inform future guideline recommendations. Adverse events related to ketamine administration in 1 included study were limited to transient increases in blood pressure. Although adverse events were not measured in the trials examining use of lithium, it has a low therapeutic index and requires patient safety monitoring. Finally, several gaps in the literature merit further study. These are described extensively in the full CPG, which is available at the Web site for the VA/DoD CPGs (30).
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